Compare DNOW & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DNOW | BHVN |
|---|---|---|
| Founded | 1862 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | 2014 | 2022 |
| Metric | DNOW | BHVN |
|---|---|---|
| Price | $12.59 | $15.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 14 |
| Target Price | $16.67 | ★ $29.08 |
| AVG Volume (30 Days) | 3.2M | ★ 3.9M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,648,000,000.00 | N/A |
| Revenue This Year | $69.47 | N/A |
| Revenue Next Year | $8.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 25.68 | N/A |
| 52 Week Low | $10.94 | $7.48 |
| 52 Week High | $17.26 | $18.57 |
| Indicator | DNOW | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 39.29 | 69.33 |
| Support Level | $11.35 | $14.83 |
| Resistance Level | $13.91 | $18.37 |
| Average True Range (ATR) | 0.44 | 1.01 |
| MACD | -0.12 | 0.15 |
| Stochastic Oscillator | 1.61 | 81.57 |
Dnow Inc is a provider of energy and industrial solutions and a distributor of pipe, valves, and fittings (PVF) and pumps, as well as fabrication, assembly, and testing of process and production equipment. It provides a broad mix of products required to build and maintain essential infrastructure and operating equipment across upstream, midstream, gas utilities, downstream, energy transition, and industrial markets, along with value-added supply chain solutions and technical product expertise supported by digital offerings through its DigitalNOW and MRCGO e-commerce platforms. The company operates mainly under the DNOW and MRC brands and has three reportable segments: the United States, which generates the majority of revenue, Canada, and International.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.